Holen Sie sich die Stockscreener-App
10.25
12.02%
1.10
Handel nachbörslich:
10.24
-0.010
-0.10%
Schlusskurs vom Vortag:
$9.15
Offen:
$9.24
24-Stunden-Volumen:
221.41K
Relative Volume:
0.40
Marktkapitalisierung:
$27.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+12.95%
1M Leistung:
+64.26%
6M Leistung:
+98.64%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.24
$10.37
1-Wochen-Bereich:
$7.961
$10.37
52-Wochen-Spanne:
$2.70
$18.00
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Vergleichen Sie QNTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
10.25 | 2.71M | 0 | 0 | 0 | 0.00 |
|
HLN
Haleon Plc Adr
|
10.80 | 48.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
163.04 | 70.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.85 | 3.54M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.11 | 45.20B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.94 | 19.42B | 16.54B | -1.64B | 749.00M | -1.45 |
Quantum Biopharma Ltd Aktie (QNTM) Neueste Nachrichten
Quantum BioPharma to Present at Upcoming Investor Conferences - TipRanks
Cathie Wood Is Betting Big on This Hidden-Gem AI Stock - The Globe and Mail
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference - GlobeNewswire
Quantum BioPharma Sets Double Conference Appearance: Key Investor Presentations Coming This May - Stock Titan
Prediction: MercadoLibre Will Beat the Market. Here's Why. - The Globe and Mail
TORONTO TEMPO MARKS ONE YEAR TO TIP-OFF WITH IMMERSIVE TEMPO LIVE EVENT - The Globe and Mail
Quantum Biopharma reports Q1 2025 financials - Investing.com
Quantum Biopharma reports Q1 2025 financials By Investing.com - Investing.com Nigeria
Quantum Biopharma Reports Q1 2025 Financial Results - TipRanks
Quantum BioPharma (QNTM) Completes Key Studies for Multiple Scle - GuruFocus
Quantum BioPharma Completes Key Studies for MS Drug Lucid-MS - TipRanks
Quantum BioPharma Completes Dosing in 90-Day Toxicity Studies for Multiple Sclerosis Drug Lucid-21-302, Advancing Toward IND Submission - Nasdaq
Quantum BioPharma Announces Completion of Dosing in 90-Day - GlobeNewswire
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis - Welland Tribune
Quantum BioPharma Ltd. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:QNTM) - Seeking Alpha
Quantum Biopharma Files Amended Complaint Against CIBC - GlobeNewswire
Quantum BioPharma (QNTM) Files Amended Complaint Over Alleged Ma - GuruFocus
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing - The Manila Times
Atlassian Q3 Earnings Surpass Expectations, Revenues Rise Y/Y - The Globe and Mail
Quantum Biopharma Ltd. Approved to Dual List on Upstream - ACCESS Newswire
Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Quantum BioPharma to Reveal Year-End Results and Key Regulatory Milestones in May 6 Update - Stock Titan
Quantum BioPharma Ltd. to Host Business Update Conference Call on May 6, 2025 - Nasdaq
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time - GlobeNewswire
Quantum BioPharma adds Kevin Malone as advisor - Investing.com Australia
Quantum BioPharma adds Kevin Malone as advisor By Investing.com - Investing.com South Africa
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor - The Manila Times
Quantum Biopharma Announces Advocate Against Naked Short - GlobeNewswire
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin ... - Bluefield Daily Telegraph
Quantum BioPharma Strengthens Defense: Short Selling Expert Kevin Malone to Combat Market Manipulation - Stock Titan
Quantum BioPharma Announces RSU Grant and Debt Settlement - TipRanks
Quantum BioPharma Corporate Update - Newsfile
1 ‘Defensive’ Cathie Wood Stock to Buy While It’s at a ‘Great Entry Point’ - The Globe and Mail
West Fraser Timber Ltd Stock Analysis: Q1 2025 Earnings and Future Outlook - The Globe and Mail
Meta Platforms (META) Can Withstand an Advertising Slowdown, Says Citigroup - The Globe and Mail
Stocks Pressured by Fears of a Tariff-Induced Slowdown - The Globe and Mail
Why ServiceNow Stock Is Gaining Today - The Globe and Mail
What to Know About Jeff Bezos’ Secret EV Startup Slate Auto - The Globe and Mail
Allied Announces April 2025 Distribution - The Globe and Mail
Rocket Lab Stock (RKLB) Soars on Major Hypersonic Tech Deals with US and UK Governments - The Globe and Mail
Abbott Laboratories (ABT) Q1 Earnings: What To Expect - The Globe and Mail
BWXT Moving Forward to Support National Security, Domestic Uranium Enrichment Mission - The Globe and Mail
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhar - GuruFocus
Quantum BioPharma (QNTM) Prevails in Legal Dispute with Former C - GuruFocus
Lithium Argentina to Release First Quarter 2025 Results on May 14, 2025 - The Globe and Mail
Quantum BioPharma wins legal battle against former CEO By Investing.com - Investing.com South Africa
Market Analysis: April 14th, 2025 - The Globe and Mail
Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold - The Globe and Mail
3 Hot New IPOs Defying the 2025 Market Slump - The Globe and Mail
Canadian Insurance Market Remains Strong Amidst Market Volatility: Aon Report - The Globe and Mail
Finanzdaten der Quantum Biopharma Ltd-Aktie (QNTM)
Es liegen keine Finanzdaten für Quantum Biopharma Ltd (QNTM) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):